ClinicalTrials HQ

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Recruiting · NCT07287397 · Registry updated 2026-09-10
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALSNutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorderRecruitingPhase 1 / Phase 22026-09-10NCT07287397

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Vector Y Therapeutics1

11 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Herbert Irving Comprehensive Cancer CenterNew YorkUnited States6
Kings College HospitalLondonUnited Kingdom29
Mayo Clinic in FloridaJacksonvilleUnited States89
Royal Hallamshire HospitalSheffieldUnited Kingdom18
Sean M. Healey & AMG Center for ALS at Massachusetts General HospitalBostonUnited States2
St Joseph's Hospital and medical Center - Barrow Neurological InstitutePhoenixUnited States1
UMC UtrechtUtrechtNetherlands42
University of California San Diego Medical CenterSan DiegoUnited States1
University of Miami School of ScienceMiamiUnited States1
University of PennsylvaniaPhiladelphiaUnited States507
UZ LeuvenLeuvenBelgium82